PURE PURE Bioscience, Inc.

0.490.05 (+10.2%)
Close: May 23, 2019

Quote

Previous Close
$0.49
Day Range
-
52 Week Range
$0.29-$0.79
Volume
-
Avg Volume
12,675
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$35.94M
Enterprise Value (EV)
$32.19M
PE Ratio
-
EV/EBITDA
-4.76
Price/Sales
18.38
Price/Book
28.06
PEG Ratio
-

Financials

Revenue
$1.77M
Gross Profit
$1.01M
EBITDA
-$6.76M
EPS, ttm
-$0.09
Profit Margin
-
Revenue/Employee
$161.27K
Next Earnings Date
-
Debt to Equity
39%
Debt
-
Cash
$926.00K
Net Debt
-

Performance

Beta
-0.35
200 Day Moving Avg
$0.49
50 Day Moving Avg
$0.44
52 Week Change
-32.63%
YTD Change
48.60%
1 Month Change
21.25%
3 Month Change
12.79%
6 Month Change
-13.39%
1 Year Change
-32.63%
2 Year Change
-55.00%
5 Year Change
-61.86%

Share Count

Shares Outstanding
74.1M
Float
49.4M
Restricted Shares
24.7M
Restricted Shares, %
33.32%

PURE Bioscience, Inc. Company Details

Sector: Health Technology

Industry: Medical Specialties

CEO: Henry R. Lambert

Website: http://www.purebio.com

Description: PURE Bioscience, Inc. engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in El Cajon, CA.

Employees: 11